Nuformix plc

Research Nuformix plc (NFX) on Bullrun: market cap GBX 5.22M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNFX
• ExchangeLSE
• CountryUnited Kingdom
• SectorHealthcare
• IndustryBiotechnology
• CurrencyGBX
• Market capGBX 5.22M
• Financial periodFY2025
• Net income-GBP 652.59K
• Free cash flow-GBP 614.61K

Valuation Snapshot

latest market cap is GBX 5.22M.

About Nuformix plc

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology.

Frequently asked questions

What is Nuformix plc's market cap?

Nuformix plc's market capitalization is GBX 5.22M.

What does Nuformix plc do?

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.